Financial Performance - The company's operating revenue for 2018 was ¥489,447,811.58, representing a 29.90% increase compared to ¥376,791,557.72 in 2017[6]. - The net profit attributable to shareholders for 2018 was ¥64,681,884.51, a 47.95% increase from ¥43,718,975.56 in 2017[6]. - The net profit after deducting non-recurring gains and losses was ¥46,976,467.38, which is an 11.79% increase from ¥42,020,955.66 in 2017[6]. - The net cash flow from operating activities for 2018 was ¥46,846,106.88, up 64.67% from ¥28,449,113.42 in 2017[6]. - The total assets at the end of 2018 were ¥817,835,805.47, an 8.62% increase from ¥752,926,669.00 at the end of 2017[6]. - The net assets attributable to shareholders at the end of 2018 were ¥611,597,582.76, a 10.08% increase from ¥555,582,698.25 at the end of 2017[6]. - The total profit for the company in 2018 was 30.94 billion yuan, reflecting a 9.5% growth compared to the previous year[35]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a year-on-year growth of 15%[122]. Dividend Policy - The company plans to distribute a cash dividend of 1.00 RMB per 10 shares to all shareholders, based on a total of 86,670,000 shares[5]. - The company plans to distribute a cash dividend of RMB 1.00 per 10 shares, totaling RMB 8,667,000, which represents 13.40% of the net profit attributable to shareholders for 2018[100]. - The cash dividend policy is in compliance with the company's articles of association and shareholder resolutions, ensuring transparency and protection of shareholder rights[96]. Product Development and Market Strategy - The company has 43 products listed in the National Medical Insurance Directory, which includes 20 Class A and 23 Class B products[28]. - The company’s main product, Panlong Qipian, is composed of 29 traditional Chinese herbs and is effective for treating various conditions such as rheumatoid arthritis and muscle injuries[29]. - The introduction of products into the National Essential Medicines List (2018 version) is expected to positively impact the company's market expansion and sales capabilities[28]. - The company has developed unique products such as Kebi Reti tablets, which address a market gap in oral medications for certain diseases[30]. - The company’s proprietary product, the Compound Acetate Cotton Phenol Tablets, is used for treating endometriosis and uterine fibroids, showcasing its diverse therapeutic applications[31]. - The company’s sales strategy includes specialized academic promotion for major products and precise distribution management for others, optimizing marketing costs[33]. - The company is actively exploring new product markets and enhancing brand image to increase sales revenue[53]. - New product launches are expected to contribute an additional 200 million RMB in revenue, with a focus on innovative drug development[116]. Research and Development - R&D investment is emphasized, with collaborations with universities and research institutions to enhance product offerings and market competitiveness[39]. - The company is currently working on several R&D projects, including the production technology for Celecoxib and the consistency evaluation of Ranitidine capsules[70]. - The company has synthesized three new derivatives of cotton phenol and obtained a U.S. patent (Patent No: 9975849B1) for one of them[71]. - The company is investing 100 million RMB in research and development for new technologies aimed at improving production processes[119]. - The company has restructured its research institute into the "Shaanxi Panlong Pharmaceutical Research Institute" to enhance its scientific research capabilities[173]. Market Expansion and Competitive Position - The company is positioned in the pharmaceutical manufacturing industry, focusing on traditional Chinese medicine and chemical preparations, contributing to its robust market presence[36]. - The marketing network covers 28 provinces, with over 300 pharmaceutical companies and sales to more than 3,000 hospitals nationwide[44]. - The company has established a comprehensive industry chain integrating "planting, research, production, supply, and sales," enhancing market competitiveness[48]. - The company is focusing on integrating resources for research and development, establishing the Panlong Pharmaceutical Research Institute to boost innovation[53]. - The company is actively pursuing market expansion, targeting an increase in distribution channels by 30% in the next fiscal year[126]. Corporate Governance and Compliance - The company is focused on complying with regulations and improving corporate governance to protect investors' rights[88]. - The company has committed to not transferring shares for 36 months from the date of stock issuance, ensuring stability in shareholding[102]. - The company is actively pursuing compliance with its commitments regarding share transfers and lock-up periods, ensuring shareholder confidence[103]. - The company has established a clear framework for managing shareholding and transfer policies to align with regulatory requirements[105]. - The company has implemented measures to ensure compliance with the China Securities Regulatory Commission's requirements regarding return measures[130]. Social Responsibility and Community Engagement - The company has been recognized as a "National Poverty Alleviation Leading Enterprise" and "Advanced Poverty Alleviation Enterprise" by the State Council and Shaanxi provincial government[159]. - The company has signed contracts for the cultivation of medicinal materials covering over 50,000 acres, benefiting more than 7,520 impoverished individuals[162]. - The company has donated 500,000 CNY to the Shaanxi Charity Association for poverty alleviation and education support[158]. - The company has provided 3.5 million CNY in educational support to impoverished students[161]. - The company is exploring new poverty alleviation models to effectively open up income channels for impoverished households[168]. Shareholding Structure - The total number of shares before the change was 86,670,000, with 75% being restricted shares[177]. - The largest shareholder, Xie Xiaolin, holds 37,171,000 restricted shares, which remain unchanged[181]. - The company had a lock-up release on November 16, 2018, with 27,829,000 shares released, representing 32.1% of the total share capital[189]. - The company’s board of directors and senior management collectively hold 43,260,000 shares, which is approximately 52.5% of the total share capital[195]. - The company has not engaged in any trust or asset management methods to control the company[189].

Financial Performance - The company's operating revenue for Q1 2019 was ¥120,534,391.24, representing a 27.89% increase compared to ¥94,246,673.75 in the same period last year[8] - Net profit attributable to shareholders was ¥11,986,886.45, up 24.69% from ¥9,613,067.73 year-on-year[8] - The net profit after deducting non-recurring gains and losses reached ¥10,489,539.40, reflecting a 27.67% increase from ¥8,215,885.68 in the previous year[8] - Basic earnings per share increased to ¥0.1383, a rise of 24.71% from ¥0.1109[8] - Total operating revenue for Q1 2019 reached ¥120,534,391.24, an increase of 28% compared to ¥94,246,673.75 in the same period last year[35] - Net profit for Q1 2019 was ¥11,986,886.45, representing a 25% increase from ¥9,613,067.73 in Q1 2018[36] - The total profit for the current period was ¥14,267,042.96, compared to ¥10,772,342.82 in the previous period, marking an increase of around 32.7%[40] Cash Flow - The net cash flow from operating activities surged by 160.00%, amounting to ¥9,613,393.35 compared to ¥3,697,480.38 in the same period last year[8] - Net cash flow from operating activities increased by 160.00% to ¥9,613,393.35, up from ¥3,697,480.38, mainly due to the growth in operating revenue[16] - The company reported cash inflows from operating activities totaling ¥148,079,261.81, compared to ¥101,777,615.07 in the previous period, which is an increase of about 45.4%[44] - The cash outflows from operating activities were ¥138,465,868.46, up from ¥98,080,134.69, indicating an increase of approximately 40.9%[44] - The company experienced a net cash outflow from investing activities of ¥19,579,010.68, compared to a larger outflow of ¥235,730,442.85 in the previous period[45] Assets and Liabilities - Total assets at the end of the reporting period were ¥835,336,416.14, a 2.14% increase from ¥817,835,805.47 at the end of the previous year[8] - The company's total liabilities increased slightly to ¥211,751,946.93 from ¥206,238,222.71, reflecting ongoing operational commitments[27] - The total assets of the company as of March 31, 2019, amounted to ¥835,336,416.14, compared to ¥817,835,805.47 at the end of the previous year[26] - The company's total liabilities stood at ¥157,699,394.66, slightly up from ¥157,394,609.28 in the previous quarter[32] Shareholder Information - The total number of common shareholders at the end of the reporting period was 16,062[12] - The largest shareholder, Xie Xiaolin, holds 42.89% of the shares, totaling 37,171,000 shares[12] - The total equity attributable to shareholders reached ¥623,145,876.32, an increase from ¥610,837,403.90 at the end of 2018[33] Research and Development - Research and development expenses rose significantly by 109.58% to ¥1,718,105.72 from ¥819,771.55, attributed to payments made according to R&D progress[16] - Research and development expenses for Q1 2019 were ¥1,718,105.72, nearly double the ¥819,771.55 spent in Q1 2018, indicating a strong focus on innovation[35] Non-Recurring Gains and Losses - The company reported non-recurring gains of ¥1,497,347.05, which included government subsidies and investment management income[9] - The company reported a substantial increase in non-operating income, which surged by 4133.07% to ¥402,868.90 from ¥9,517.18, primarily due to government subsidies received[16] Inventory and Cash Management - The cash and cash equivalents decreased to ¥75,157,539.57 from ¥85,123,156.90, indicating a reduction in liquidity[25] - The company’s inventory increased to ¥45,008,378.78 from ¥39,902,963.79, suggesting a buildup in stock levels[25] - The company's cash and cash equivalents decreased to ¥60,004,324.06 from ¥73,544,910.18, a decline of about 18%[29] Other Financial Metrics - The company reported a gross profit margin of approximately 10% for Q1 2019, compared to 11% in the same quarter last year, reflecting increased costs[35] - The accounts receivable balance was ¥163,164,760.08, slightly down from ¥168,687,810.15, indicating improved collection efforts[29] Reporting Practices - The first quarter report was not audited, indicating that the figures may be subject to change upon final review[51] - The company has not applied new financial instrument standards or new revenue recognition standards, indicating stability in reporting practices[50]

1 陕西盘龙药业集团股份有限公司 2018 年第三季度报告正文 陕西盘龙药业集团股份有限公司 2018 年第三季度报告正文 证券代码：002864 证券简称：盘龙药业 公告编号：2018-063 陕西盘龙药业集团股份有限公司 2018 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人谢晓林、主管会计工作负责人祝凤鸣及会计机构负责人(会计主 管人员)吴继文声明：保证季度报告中财务报表的真实、准确、完整。 2 陕西盘龙药业集团股份有限公司 2018 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 819,029,870.69 | | 752,926,669.00 | 8.78% | ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2018, representing a year-on-year increase of 15%[14]. - The net profit attributable to shareholders was RMB 80 million, up 20% compared to the same period last year[14]. - The company aims to achieve a revenue growth target of 20% for the full year 2018[14]. - The gross margin for the first half of 2018 was reported at 45%, a slight decrease from 47% in the previous year[14]. - The company's operating revenue for the reporting period was ¥208,339,577.45, representing a 29.13% increase compared to ¥161,346,961.24 in the same period last year[20]. - The net profit attributable to shareholders was ¥29,999,006.58, reflecting a significant increase of 71.07% from ¥17,535,728.68 in the previous year[20]. - The basic earnings per share rose to ¥0.35, up 29.63% from ¥0.27 in the previous year[20]. - The total profit of CNY 35,161,267.20, which is an increase of 67.2% compared to CNY 21,025,823.45 in the previous year[147]. - The company achieved investment income of CNY 4,524,387.23, with no comparable figure from the previous year[147]. Market Expansion and Strategy - The company plans to expand its market presence by entering three new provinces by the end of 2018[14]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market share[14]. - The company has implemented a new procurement strategy to reduce costs by 5% across its supply chain[14]. - The sales strategy includes specialized academic promotion for key products and precise distribution management for other drugs, optimizing marketing costs[34][35]. - The company is actively exploring new product markets and enhancing its brand image to strengthen its market position[56]. - The company plans to establish a national trading market for Astragalus, integrating planting, storage, processing, and logistics[57]. Research and Development - Research and development expenses increased by 25% to RMB 30 million, focusing on new drug formulations and technologies[14]. - The company will continue to invest heavily in drug research and development to expand its product line, despite the inherent uncertainties[86]. - The company completed clinical verification for the product "Panlong Seven Tablets" with 137 cases enrolled, enhancing its market influence[57]. Inventory and Assets - Inventory increased by 50.02%, attributed to higher sales volume and routine maintenance of production facilities[40]. - The total assets at the end of the reporting period were ¥792,729,173.74, marking a 5.29% increase from ¥752,926,669.00 at the end of the previous year[20]. - Accounts receivable increased by 29.39% to ¥172,387,413.41, making up 21.75% of total assets, attributed to sales revenue growth[68]. - Inventory rose by 76.56% to ¥47,953,184.11, representing 6.05% of total assets, due to increased sales scale and routine maintenance[68]. Social Responsibility and Community Engagement - The company has established a partnership with Xichuan Village in Shaanxi Province and various towns in Huachi County, Gansu Province, focusing on targeted poverty alleviation efforts[112]. - A total of 320 individuals have been trained through 14 training sessions aimed at enhancing local agricultural practices and increasing income[112]. - The company has committed to purchasing all harvested medicinal materials from local farmers, ensuring a stable income source for them[112]. - The company emphasizes a dual approach to poverty alleviation, combining "blood transfusion" and "blood production" strategies to ensure sustainable development[114]. Financial Health and Stability - The company has not engaged in any significant non-raised fund investment projects during the reporting period[81]. - The overall financial health of the company appears stable, with a focus on maintaining equity levels[168]. - The company maintains a continuous operation capability for at least 12 months from the report date, with no significant issues affecting its operational capacity[176]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 22,538[124]. - The largest shareholder, Xie Xiaolin, holds 42.89% of the shares, totaling 37,171,000 shares[124]. - The total number of shares is 86,670,000, with 75.00% being limited shares[122]. - The company did not distribute cash dividends or issue bonus shares during the reporting period[91]. Risks and Challenges - The company faces industry policy risks due to stringent regulations affecting the pharmaceutical sector, which may impact future development[85]. - The company is also exposed to drug price reduction risks, influenced by policy-driven price cuts and market competition[86]. - The company plans to enhance its quality management to mitigate product quality safety risks arising from new regulations[86].

Financial Performance - The company's revenue for Q1 2018 reached ¥94,246,673.75, representing a 41.57% increase compared to ¥66,572,071.94 in the same period last year[9] - Net profit attributable to shareholders was ¥9,613,067.73, up 39.52% from ¥6,890,112.93 year-on-year[9] - The net profit after deducting non-recurring gains and losses was ¥8,215,885.68, reflecting a 24.47% increase from ¥6,600,454.01 in the previous year[9] - Basic and diluted earnings per share were both ¥0.1109, an increase of 4.62% from ¥0.1060 in the previous year[9] - The company expects net profit attributable to shareholders for the first half of 2018 to range from ¥1,800,000 to ¥2,200,000, representing a growth of 2.65% to 25.46% compared to the same period in 2017[23] Cash Flow and Assets - The net cash flow from operating activities was ¥3,697,480.38, showing a significant increase of 91.29% compared to ¥1,932,939.29 in the same quarter last year[9] - Total assets at the end of the reporting period were ¥767,819,109.91, a 1.98% increase from ¥752,926,669.00 at the end of the previous year[9] - Net assets attributable to shareholders amounted to ¥565,195,765.98, up 1.73% from ¥555,582,698.25 at the end of the last year[9] - The company's cash and cash equivalents decreased by 79.15% to ¥62,846,714.40 due to the purchase of wealth management products[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,892[13] - The largest shareholder, Xie Xiaolin, holds 42.89% of the shares, totaling 37,171,000 shares[13] Operating Performance - Operating revenue increased by 41.57% to ¥94,246,673.75, primarily driven by sales growth[17] - Operating costs rose by 46.11% to ¥29,899,966.47, in line with increased sales[17] - Net cash flow from operating activities improved by 91.29% to ¥3,697,480.38, attributed to higher operating revenue[17] Investment Strategy and Risk Management - The company has adopted a prudent investment strategy, focusing on low-risk wealth management products to enhance capital efficiency[18] - The financial department will continuously monitor investment products to mitigate risks affecting capital safety[20] Compliance and Commitments - The company has no overdue commitments from controlling shareholders or related parties during the reporting period[22] - There were no violations regarding external guarantees during the reporting period[24] - The company has not engaged in non-operating fund occupation by controlling shareholders or related parties[25] Non-Operating Income - The company reported non-operating income of ¥1,864,832.29 from fair value changes of financial assets, contributing to its overall financial performance[10]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2017, representing a year-on-year growth of 15%[6]. - The net profit attributable to shareholders was RMB 200 million, an increase of 10% compared to the previous year[6]. - The company's operating revenue for 2017 was approximately ¥376.79 million, representing a 23.37% increase compared to ¥305.43 million in 2016[20]. - The net profit attributable to shareholders for 2017 was approximately ¥43.72 million, which is a 10.60% increase from ¥39.53 million in 2016[20]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the year, representing a growth of 20% compared to the previous year[125]. - The company reported a net profit from continuing operations of CNY 43,718,975.56 for the current year[140]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of RMB 1.00 per 10 shares, totaling approximately RMB 8.67 million[6]. - In 2017, the company distributed cash dividends of RMB 8,667,000, which is 19.82% of the net profit attributable to shareholders of RMB 43,718,975.56[114]. - The company aims to maintain a minimum cash dividend ratio of 20% during its growth phase, considering significant capital expenditures[118]. - The company has committed to a cash dividend policy, prioritizing cash dividends over stock dividends, as outlined in the revised articles of association[133]. Market Expansion and Strategy - The company is focusing on expanding its market presence in Southeast Asia, targeting a 25% increase in market share by 2019[6]. - The company anticipates a revenue growth forecast of 20% for 2018, driven by new product launches and market expansion efforts[6]. - The company is actively exploring acquisition opportunities to enhance its product portfolio and market reach, with a budget of RMB 200 million allocated for potential acquisitions[6]. - A strategic acquisition of a local pharmaceutical company was completed, enhancing the company's product portfolio and expected to generate 200 million RMB in additional revenue[130]. - The company plans to enhance its digital marketing efforts, aiming for a 20% increase in online sales channels[128]. Research and Development - The company has invested RMB 50 million in R&D for new technologies aimed at improving production efficiency by 30%[6]. - The company is actively developing 13 research projects, including glucosamine hydrochloride capsules and celecoxib capsules, with some projects entering clinical trial phases[67]. - Research and development expenditure increased by 30%, reflecting the company's focus on innovation and new technology[127]. - The company is focused on the research and development of traditional Chinese medicine, with a strong emphasis on unique herbal ingredients sourced from the Qinba Mountains[30]. Operational Efficiency - The company is committed to reducing operational costs by 15% through improved efficiency measures in the supply chain[126]. - The company employs a "production-based procurement" model, maintaining a 20-35 day inventory based on production plans and market demand, ensuring efficient raw material management[36]. - Strategic partnerships with local distributors are expected to enhance distribution channels, aiming for a 15% reduction in logistics costs[6]. Social Responsibility and Environmental Management - The company actively engaged in social responsibility initiatives, including free medical check-ups and treatments for villagers in poverty-stricken areas[167]. - The company established a charity fund to assist impoverished villages, providing support for orphans and impoverished students[169]. - The company has implemented strict environmental protection measures, adhering to pollution discharge standards for waste gas, wastewater, noise, and solid waste[178]. - The company aims to combine poverty alleviation with ecological civilization and rural development, actively seeking funding for project construction[176]. Shareholder and Governance - The company emphasizes compliance with regulations and improving corporate governance to protect investors' rights[106]. - The controlling shareholder, Xie Xiaolin, has pledged to maintain their shareholding without transfer or repurchase for 12 months following the stock issuance[121]. - The company has established a commitment to maintain stock price stability through potential repurchase actions if certain conditions are met[123]. - The company will adhere to fair and reasonable principles in any unavoidable related party transactions[132].